Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre

D. Gareth Evans,Kate Green,George J. Burghel,Claire Forde,Fiona Lalloo,Helene Schlecht,Emma R. Woodward

DOI: https://doi.org/10.1007/s10689-024-00360-9

2024-03-14

Familial Cancer

Abstract:In the 33 years since the first diagnostic cancer predisposition gene (CPG) tests in the Manchester Centre for Genomic Medicine, there has been substantial changes in the identification of index cases and cascade testing for at-risk family members. National guidelines in England and Wales are usually determined from the National Institute of healthcare Evidence and these have impacted on the thresholds for testing BRCA1/2 in Hereditary Breast Ovarian Cancer (HBOC) and in determining that all cases of colorectal and endometrial cancer should undergo screening for Lynch syndrome. Gaps for testing other CPGs relevant to HBOC have been filled by the UK Cancer Genetics Group and CanGene-CanVar project (web ref. https://www.cangene-canvaruk.org/). We present time trends (1990–2020) of identification of index cases with germline CPG variants and numbers of subsequent cascade tests, for BRCA1 , BRCA2 , and the Lynch genes ( MLH1 , MSH2 , MSH6 and PMS2 ) For BRCA1/2 there was a definite increase in the proportion of index cases with ovarian cancer only and pre-symptomatic index tests both doubling from 16 to 32% and 3.2 to > 8% respectively. A mean of 1.73–1.74 additional family tests were generated for each BRCA1/2 index case within 2 years. Overall close to one positive cascade test was generated per index case resulting in > 1000 risk reducing surgery operations. In Lynch syndrome slightly more cascade tests were performed in the first two years potentially reflecting the increased actionability in males with 42.2% of pre-symptomatic tests in males compared to 25.8% in BRCA1/2 ( p < 0.0001).

oncology,genetics & heredity

What problem does this paper attempt to address?

This paper aims to explore and evaluate the time trends of hereditary breast - ovarian cancer (HBOC) and Lynch syndrome family screening carried out at the Manchester Centre for Genomic Medicine (MCGM) in the UK and their relationship with guideline changes. Specifically, the study focused on the number of index cases with pathogenic gene variants identified, as well as the number and results of subsequent cascade tests at the family level from 1990 to 2020. ### Research Background - **Development of Gene Testing**: Since 1990, with the emergence of the first Cancer Predisposition Gene (CPG) test, gene testing technology has been continuously advancing, especially in the detection of BRCA1/2 and Lynch - syndrome - related genes (such as MLH1, MSH2, MSH6, PMS2). - **Changes in Guidelines**: Guidelines issued by the National Institute for Health and Care Excellence (NICE) in the UK and other institutions have adjusted the threshold for gene testing many times, from the initial 20% to 10% or even lower, in order to improve the coverage and efficiency of testing. ### Research Objectives 1. **Evaluate Time Trends**: Analyze the changes in the number of index case identifications and family - level cascade tests for BRCA1/2 and Lynch - syndrome - related genes from 1990 to 2020. 2. **Impact of Guidelines**: Explore how guideline changes in different time periods affect the implementation and effectiveness of gene testing. 3. **Clinical Application**: Evaluate the practical application effects of gene testing in cancer prevention and early detection, especially for the screening and risk management of high - risk family members. ### Main Findings - **BRCA1/2**: - 1,600 index cases carrying BRCA1/2 variants were identified. - The proportion of ovarian cancer patients tested increased significantly, from 16.5% to 32%. - The proportion of asymptomatic testing also increased, from 3.2% to more than 8%. - Each index case generated an average of 1.73 to 1.74 additional family tests. - Overall, each index case generated approximately one positive cascade test, resulting in more than 1,000 risk - reduction surgeries. - **Lynch Syndrome**: - 625 index cases carrying MMR gene variants were identified. - Colorectal cancer patients accounted for the majority, but since 2013, the proportion of endometrial cancer patients tested has increased. - The proportion of male patients was relatively high, about 46%. - Each index case generated an average of 1.63 to 2.13 additional family tests. - The proportion of cascade tests in male patients was higher, at 42.2%, compared to 25.8% for BRCA1/2. ### Discussion - **Evolution of Gene Testing**: Advances in gene testing technology and adjustments in guidelines have greatly promoted the development of clinical cancer genetics. - **Treatment and Prevention**: Gene testing not only helps with treatment decisions for index cases but also provides opportunities for high - risk family members to prevent and detect cancer early. - **Challenges of Family Testing**: Although mainstream testing has increased the identification rate of index cases, the coverage of family - level cascade tests may be affected for various reasons (such as patient health status, refusal of referral, etc.). ### Conclusion This study shows the progress and challenges of MCGM in HBOC and Lynch - syndrome family screening over the past 33 years. Through gene testing, it is possible not only to provide treatment and management strategies for index cases but also to provide opportunities for high - risk family members to prevent and detect early, thereby bringing individual and social health - economic benefits.

Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre

Timely targeted testing for hereditary cancer syndromes - Importance of clinician-facilitated cascade testing in the first year post-diagnosis

Identification of people with Lynch syndrome from those presenting with colorectal cancer in England: baseline analysis of the diagnostic pathway

Challenges and opportunities for Lynch syndrome cascade testing in the United States

Detection of BRCA1 Pathogenic Variant in a 24-Year-Old Endometrial Cancer Patient: Risks of Several Hereditary Tumor Syndromes Assessed Using Germline Multigene Panel Testing

A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome

Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics

Lynch syndrome diagnostic testing pathways in endometrial cancers: a nationwide English registry-based study

Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system

Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care

Strategies to improve implementation of cascade testing in hereditary cancer syndromes: a systematic review

Expert and Advocacy Group Consensus Findings on the Horizon of Public Health Genetic Testing

BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial

Barricades to aiding cascading: Patient-reported barriers to uptake in the context of clinician-facilitated cascade testing for hereditary cancer syndromes.

Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer

Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs

Economic evaluation of extended panel analysis in cancer patients with historical NHS diagnostic germline genetic testing - A modeling study based on real-world data

Exome Sequencing Identifies Carriers of the Autosomal Dominant Cancer Predisposition Disorders Beyond Current Practice Guideline Recommendations

Use of comprehensive next-generation sequencing to identify pathogenic germline variants with therapeutic relevance in metastatic breast cancer.

British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom

Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review